V7B Stock Overview
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Assembly Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.90 |
| 52 Week High | US$17.95 |
| 52 Week Low | US$7.63 |
| Beta | 0.59 |
| 11 Month Change | -8.55% |
| 3 Month Change | 8.59% |
| 1 Year Change | 73.92% |
| 33 Year Change | -42.66% |
| 5 Year Change | n/a |
| Change since IPO | -92.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| V7B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.2% | 0.8% | -1.3% |
| 1Y | 73.9% | -17.5% | 7.4% |
Return vs Industry: V7B exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: V7B exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| V7B volatility | |
|---|---|
| V7B Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V7B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: V7B's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
Assembly Biosciences, Inc. Fundamentals Summary
| V7B fundamental statistics | |
|---|---|
| Market cap | €91.08m |
| Earnings (TTM) | -€38.93m |
| Revenue (TTM) | €27.02m |
3.3x
P/S Ratio-2.3x
P/E RatioIs V7B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V7B income statement (TTM) | |
|---|---|
| Revenue | US$28.33m |
| Cost of Revenue | US$52.66m |
| Gross Profit | -US$24.33m |
| Other Expenses | US$16.47m |
| Earnings | -US$40.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.42 |
| Gross Margin | -85.90% |
| Net Profit Margin | -144.05% |
| Debt/Equity Ratio | 0% |
How did V7B perform over the long term?
See historical performance and comparison